• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

褪黑素通过抑制 AKT/hTERT 信号通路协同 BRAF 靶向药物 dabrafenib 治疗间变性甲状腺癌。

Melatonin synergizes BRAF-targeting agent dabrafenib for the treatment of anaplastic thyroid cancer by inhibiting AKT/hTERT signalling.

机构信息

Shanghai Center for Thyroid Disease, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.

Department of Endocrinology, Children's Hospital of Nanjing Medical University, Nanjing, China.

出版信息

J Cell Mol Med. 2020 Oct;24(20):12119-12130. doi: 10.1111/jcmm.15854. Epub 2020 Sep 15.

DOI:10.1111/jcmm.15854
PMID:32935463
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7579709/
Abstract

As a selective inhibitor of BRAF kinase, dabrafenib has shown potent anti-tumour activities in patients with BRAFV600E mutant anaplastic thyroid cancer. However, the resistance of thyroid cancer cells to dabrafenib limited its therapeutic effect. The effects of melatonin and dabrafenib as monotherapy or in combination on the proliferation, cell cycle arrest, apoptosis, migration and invasion of anaplastic thyroid cancer cells were examined. The molecular mechanism involved in drug combinations was also revealed. Melatonin enhanced dabrafenib-mediated inhibition of cell proliferation, migration and invasion, and promoted dabrafenib-induced apoptosis and cell cycle arrest in anaplastic thyroid cancer cells. Molecular mechanistic studies further uncovered that melatonin synergized with dabrafenib to inhibit AKT and EMT signalling pathways. Furthermore, melatonin and dabrafenib synergistically inhibited the expression of hTERT, and the inhibition of cell viability and the induction of cell cycle arrest mediated by the combination of these two drugs were reversed by hTERT overexpression. Taken together, our results demonstrated that melatonin synergized the anti-tumour effect of dabrafenib in human anaplastic thyroid cancer cells by inhibiting multiple signalling pathways, and provided new insights in exploring the potential therapeutic targets for the treatment of anaplastic thyroid cancer.

摘要

达布拉非尼作为 BRAF 激酶的选择性抑制剂,在 BRAFV600E 突变型间变性甲状腺癌患者中显示出强大的抗肿瘤活性。然而,甲状腺癌细胞对达布拉非尼的耐药性限制了其治疗效果。本研究旨在探讨褪黑素和达布拉非尼单药或联合用药对间变性甲状腺癌细胞增殖、细胞周期阻滞、凋亡、迁移和侵袭的影响,并揭示药物联合作用的分子机制。褪黑素增强了达布拉非尼对间变性甲状腺癌细胞增殖、迁移和侵袭的抑制作用,并促进了达布拉非尼诱导的细胞凋亡和细胞周期阻滞。分子机制研究进一步揭示,褪黑素与达布拉非尼协同抑制 AKT 和 EMT 信号通路。此外,褪黑素和达布拉非尼协同抑制端粒酶反转录酶(hTERT)的表达,而过表达 hTERT 可逆转这两种药物联合抑制细胞活力和诱导细胞周期阻滞的作用。综上所述,本研究结果表明,褪黑素通过抑制多条信号通路增强了达布拉非尼在人源性间变性甲状腺癌细胞中的抗肿瘤作用,为探索治疗间变性甲状腺癌的潜在治疗靶点提供了新的思路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e64/7579709/f5873d6c4b0f/JCMM-24-12119-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e64/7579709/421a9a9b4f5b/JCMM-24-12119-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e64/7579709/8f5affaf6c97/JCMM-24-12119-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e64/7579709/a2de473ffcb0/JCMM-24-12119-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e64/7579709/e394ce1244c7/JCMM-24-12119-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e64/7579709/70312ebbc758/JCMM-24-12119-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e64/7579709/f5873d6c4b0f/JCMM-24-12119-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e64/7579709/421a9a9b4f5b/JCMM-24-12119-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e64/7579709/8f5affaf6c97/JCMM-24-12119-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e64/7579709/a2de473ffcb0/JCMM-24-12119-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e64/7579709/e394ce1244c7/JCMM-24-12119-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e64/7579709/70312ebbc758/JCMM-24-12119-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e64/7579709/f5873d6c4b0f/JCMM-24-12119-g006.jpg

相似文献

1
Melatonin synergizes BRAF-targeting agent dabrafenib for the treatment of anaplastic thyroid cancer by inhibiting AKT/hTERT signalling.褪黑素通过抑制 AKT/hTERT 信号通路协同 BRAF 靶向药物 dabrafenib 治疗间变性甲状腺癌。
J Cell Mol Med. 2020 Oct;24(20):12119-12130. doi: 10.1111/jcmm.15854. Epub 2020 Sep 15.
2
Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.褪黑素通过抑制 iNOS/hTERT 信号和癌症干细胞特性与 BRAF 靶向药物 vemurafenib 协同作用治疗黑色素瘤。
J Exp Clin Cancer Res. 2019 Feb 4;38(1):48. doi: 10.1186/s13046-019-1036-z.
3
Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.托林2作用于间变性甲状腺癌中失调的信号通路,抑制肿瘤生长和转移。
Oncotarget. 2015 Jul 20;6(20):18038-49. doi: 10.18632/oncotarget.3833.
4
Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.激活的BRAF和MEK抑制对人间变性甲状腺癌细胞生长的阻滞作用
Int J Oncol. 2016 Dec;49(6):2303-2308. doi: 10.3892/ijo.2016.3723. Epub 2016 Oct 7.
5
Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature.达拉非尼联合曲美替尼治疗间变性甲状腺癌:病例报告及文献复习。
Curr Probl Cancer. 2021 Apr;45(2):100668. doi: 10.1016/j.currproblcancer.2020.100668. Epub 2020 Oct 22.
6
Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma.达巴非尼和厄洛替尼联合治疗间变性甲状腺癌的效果。
Endocr Relat Cancer. 2022 May 9;29(6):307-319. doi: 10.1530/ERC-22-0022.
7
Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.BKM120与Prima-1Met通过抑制PI3K/AKT/mTOR和CPSF4/hTERT信号通路以及重新激活突变型P53产生协同抗肿瘤作用。
Cell Physiol Biochem. 2018;45(5):1772-1786. doi: 10.1159/000487786. Epub 2018 Feb 23.
8
S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.S100A4基因敲除使携带BRAFV600E/Mt的间变性甲状腺癌细胞对维莫非尼敏感。
Cell Physiol Biochem. 2018;49(3):1143-1162. doi: 10.1159/000493296. Epub 2018 Sep 7.
9
AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.在同时携带野生型和突变型(V600E)BRAF基因的结肠癌细胞中,AKT在BRAF抑制剂索拉非尼对抗达拉非尼的拮抗作用中起关键作用。
Biochem Biophys Res Commun. 2017 Jul 15;489(1):14-20. doi: 10.1016/j.bbrc.2017.05.110. Epub 2017 May 20.
10
Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.靶向PI3K/AKT/mTOR信号通路可克服达拉非尼对获得性BRAF抑制剂耐药的黑色素瘤细胞侵袭行为的刺激作用。
Int J Oncol. 2016 Sep;49(3):1164-74. doi: 10.3892/ijo.2016.3594. Epub 2016 Jun 30.

引用本文的文献

1
Anaplastic thyroid cancer: Genetic roles, targeted therapy, and immunotherapy.间变性甲状腺癌:基因作用、靶向治疗及免疫治疗
Genes Dis. 2024 Aug 30;12(4):101403. doi: 10.1016/j.gendis.2024.101403. eCollection 2025 Jul.
2
Multi-omics data analysis reveals the complex roles of age in differentiated thyroid cancer.多组学数据分析揭示了年龄在分化型甲状腺癌中的复杂作用。
Heliyon. 2024 Jun 26;10(13):e33595. doi: 10.1016/j.heliyon.2024.e33595. eCollection 2024 Jul 15.
3
Melatonin and Its Role in the Epithelial-to-Mesenchymal Transition (EMT) in Cancer.

本文引用的文献

1
Novel treatments for anaplastic thyroid carcinoma.间变性甲状腺癌的新型治疗方法。
Gland Surg. 2020 Jan;9(Suppl 1):S28-S42. doi: 10.21037/gs.2019.10.18.
2
A Systematic Review of Phase II Targeted Therapy Clinical Trials in Anaplastic Thyroid Cancer.间变性甲状腺癌II期靶向治疗临床试验的系统评价
Cancers (Basel). 2019 Jul 4;11(7):943. doi: 10.3390/cancers11070943.
3
Shikonin inhibits proliferation, migration, invasion and promotes apoptosis in NCI-N87 cells via inhibition of PI3K/AKT signal pathway.紫草素通过抑制 PI3K/AKT 信号通路抑制 NCI-N87 细胞的增殖、迁移、侵袭,促进凋亡。
褪黑素及其在癌症上皮-间质转化(EMT)中的作用
Cancers (Basel). 2024 Feb 27;16(5):956. doi: 10.3390/cancers16050956.
4
Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications.健康与疾病中的蛋白质翻译后修饰:功能、调控机制及治疗意义
MedComm (2020). 2023 May 2;4(3):e261. doi: 10.1002/mco2.261. eCollection 2023 Jun.
5
Combined targeted therapy and immunotherapy in anaplastic thyroid carcinoma with distant metastasis: A case report.联合靶向治疗与免疫治疗用于远处转移的间变性甲状腺癌:一例报告
World J Clin Cases. 2022 Apr 26;10(12):3849-3855. doi: 10.12998/wjcc.v10.i12.3849.
6
Calcium acts as a central player in melatonin antitumor activity in sarcoma cells.钙在褪黑素抑制肉瘤细胞肿瘤活性的过程中发挥核心作用。
Cell Oncol (Dordr). 2022 Jun;45(3):415-428. doi: 10.1007/s13402-022-00674-9. Epub 2022 May 2.
7
Advances in targeted therapy for anaplastic thyroid carcinoma.甲状腺间变大细胞癌的靶向治疗进展。
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021 Dec 25;50(6):685-693. doi: 10.3724/zdxbyxb-2021-0249.
8
Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update.新型甲状腺癌抑制剂治疗方法的研究进展。
Int J Mol Sci. 2021 Oct 31;22(21):11829. doi: 10.3390/ijms222111829.
9
Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer.褪黑素下调 KRAS 突变型非小细胞肺癌中 PD-L1 的表达并调节肿瘤免疫。
Int J Mol Sci. 2021 May 26;22(11):5649. doi: 10.3390/ijms22115649.
10
Anti-Warburg Effect of Melatonin: A Proposed Mechanism to Explain its Inhibition of Multiple Diseases.褪黑素的抗 Warburg 效应:解释其抑制多种疾病的一种机制。
Int J Mol Sci. 2021 Jan 14;22(2):764. doi: 10.3390/ijms22020764.
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2662-2669. doi: 10.1080/21691401.2019.1632870.
4
Ku80 promotes melanoma growth and regulates antitumor effect of melatonin by targeting HIF1-α dependent PDK-1 signaling pathway.Ku80 通过靶向 HIF1-α 依赖性 PDK-1 信号通路促进黑色素瘤生长并调节褪黑素的抗肿瘤作用。
Redox Biol. 2019 Jul;25:101197. doi: 10.1016/j.redox.2019.101197. Epub 2019 Apr 20.
5
LRG‑1 enhances the migration of thyroid carcinoma cells through promotion of the epithelial‑mesenchymal transition by activating MAPK/p38 signaling.LRG-1 通过激活 MAPK/p38 信号通路促进甲状腺癌细胞的上皮-间质转化,从而增强其迁移能力。
Oncol Rep. 2019 Jun;41(6):3270-3280. doi: 10.3892/or.2019.7123. Epub 2019 Apr 17.
6
Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.褪黑素通过抑制 iNOS/hTERT 信号和癌症干细胞特性与 BRAF 靶向药物 vemurafenib 协同作用治疗黑色素瘤。
J Exp Clin Cancer Res. 2019 Feb 4;38(1):48. doi: 10.1186/s13046-019-1036-z.
7
Melatonin inhibits MLL-rearranged leukemia via RBFOX3/hTERT and NF-κB/COX-2 signaling pathways.褪黑素通过 RBFOX3/hTERT 和 NF-κB/COX-2 信号通路抑制 MLL 重排白血病。
Cancer Lett. 2019 Feb 28;443:167-178. doi: 10.1016/j.canlet.2018.11.037. Epub 2018 Dec 11.
8
Therapeutic advances in anaplastic thyroid cancer: a current perspective.间变性甲状腺癌的治疗进展:现状与展望。
Mol Cancer. 2018 Oct 23;17(1):154. doi: 10.1186/s12943-018-0903-0.
9
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
10
Telomerase reverse transcriptase induced thyroid carcinoma cell proliferation through PTEN/AKT signaling pathway.端粒酶逆转录酶通过 PTEN/AKT 信号通路诱导甲状腺癌细胞增殖。
Mol Med Rep. 2018 Aug;18(2):1345-1352. doi: 10.3892/mmr.2018.9119. Epub 2018 Jun 1.